LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LNSR 12.09.2024

Full Press ReleaseSEC FilingsOur LNSR Tweets

About Gravity Analytica

Recent News

  • 01.02.2025 - LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • 11.26.2024 - LENSAR to Participate in the BTIG 4th Annual Ophthalmology Day
  • 11.07.2024 - LENSAR Inc. Third Quarter 2024 Results Conference Call

Recent Filings

  • 11.14.2024 - SC 13G/A Statement of Beneficial Ownership by Certain Investors
  • 11.07.2024 - 8-K Current report
  • 11.07.2024 - 10-Q Quarterly report [Sections 13 or 15(d)]

ORLANDO, Fla.,Dec. 09, 2024(GLOBE NEWSWIRE) --LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted four newly-hired non-executive employees stock options to purchase an aggregate of 2,475 shares of the Company’s common stock. The options were granted as of December 8, 2024, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $7.70 per share, which is equal to the closing price of the Company’s common stock on the grant date. The options vest as to 25% of the total amount of the award on the one-year anniversary of the vesting commencement date ofDecember 2, 2024and in thirty-six substantially equal monthly installments thereafter, subject to the new employee’s continued service with the company. Each stock option has a 10-year term. The options are subject to the terms and conditions of LENSAR’s 2024 Employment Inducement Incentive Award Plan and a stock option agreement covering the grant.

AboutLENSAR

LENSARis a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure.LENSARhas developed its ALLY Robotic Cataract Laser SystemTM as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and integrating AI into proprietary imaging and software. ALLY is designed to transform premium cataract surgery by utilizing LENSAR’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reducing overhead. ALLY includes LENSAR’s proprietary Streamline®software technology, which is designed to guide surgeons to achieve better outcomes.

Contacts:Lee Roth/Cameron Radinovic
Thomas R. Staab, II, CFOBurns McClellanforLENSAR
ir.contact@lensar.comlroth@burnsmc.com/cradinovic@burnsmc.com

Primary Logo

Source: LENSAR, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com